Novartis updates pediatric asciminib CML trial; opens new schizophrenia drug study

Two Novartis-sponsored trials had registry updates in the week ending November 9, 2026.

• Asciminib, a Phase 1/2 oral therapy for pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase previously treated with one or more tyrosine kinase inhibitors¹, remains active but not recruiting. The study enrolled 46 participants (actual)¹ and its primary completion is estimated for September 3, 2027.
• XEP527, an investigational drug for stable schizophrenia, is recruiting under a Phase 1 design described as a randomized, participant and investigator-blinded, placebo-controlled, multiple ascending dose study². The trial plans to enroll 36 participants across three dosing cohorts², with a primary outcome tracking incidence of adverse events and serious adverse events, including changes in vital signs, electrocardiograms and laboratory values, over approximately 56 days².